Abstract
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer from exacerbations. Severe exacerbations are related to a significantly worse survival outcome. This review summarises the current knowledge on the different aspects of COPD exacerbations. The impact of risk factors and triggers such as smoking, severe airflow limitation, bronchiectasis, bacterial and viral infections and comorbidities is discussed. More severe exacerbations should be treated with β-agonists and anticholinergics as well as systemic corticosteroids. Antibiotic therapy should only be given to patients with presumed bacterial infection. Noninvasive ventilation is indicated in patients with respiratory failure. Smoking cessation is key to prevent further COPD exacerbations. Other aspects include choice of pharmacotherapy, including bronchodilators, inhaled corticosteroids, phosphodiesterase-4 inhibitors, long-term antibiotics and mucolytics. Better education and self-management as well as increased physical activity are important. Influenza and pneumococcal vaccination is recommended. Treatment of hypoxaemia and hypercapnia reduce the rate of COPD exacerbations, while most interventional bronchoscopic therapies increase exacerbation risk within the first months after the procedure.
Abstract
This article highlights the importance of preventing exacerbations of COPD http://ow.ly/ODQp30i5Cel
Footnotes
Author contributions: All authors contributed to the content of this manuscript and approved the final version to be submitted.
Number 3 in the Series “Acute exacerbations in pulmonary medicine” Edited by Michael Kreuter and Vincent Cottin
Previous articles in this series: No. 1: Kondoh Y, Cottin V, Brown KK. Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir Rev 2017; 26: 170050. No. 2: Savale L, Weatherald J, Jäis X, et al. Acute decompensated pulmonary hypertension. Eur Respir Rev 2017; 26: 170092.
Conflict of interest: C. Viniol has received personal fees from Novartis and Mundipharma, outside the submitted work. C.F. Vogelmeier has received personal fees from Almirall, Cipla, Berlin Chemie/Menarini, CSL Behring and Teva. He has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Mundipharma, Novartis and Takeda. He has received grants from the German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, outside the submitted work.
Provenance: Commissioned article, peer reviewed.
- Received September 6, 2017.
- Accepted January 11, 2018.
- Copyright ©ERS 2018.
ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.